K
Kuiying Xu
Researcher at Saarland University
Publications - 5
Citations - 239
Kuiying Xu is an academic researcher from Saarland University. The author has contributed to research in topics: Hydroxysteroid dehydrogenase & Steroid hormone. The author has an hindex of 4, co-authored 5 publications receiving 219 citations.
Papers
More filters
Journal ArticleDOI
17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Sandrine Marchais-Oberwinkler,Claudia Henn,Gabriele Möller,Tobias Klein,Matthias Negri,Alexander Oster,Alessandro Spadaro,Ruth Werth,Marie Wetzel,Kuiying Xu,Martin Frotscher,Rolf W. Hartmann,Jerzy Adamski +12 more
TL;DR: An overview of functional and structural aspects for the different 17β-HSDs is given and the selective inhibition of the concerned enzymes might provide an effective treatment and a good alternative to the existing endocrine therapies.
Journal ArticleDOI
Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.
Sandrine Marchais-Oberwinkler,Kuiying Xu,Marie Wetzel,Enrico Perspicace,Matthias Negri,Arne Meyer,Alex Odermatt,Gabriele Möller,Jerzy Adamski,Rolf W. Hartmann +9 more
TL;DR: The optimization of human 17β-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker between the amide moiety and the phenyl group is reported.
Journal ArticleDOI
Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
TL;DR: A series of new nonsteroidal and achiral 17β-HSD2 inhibitors, namely N-benzyl-diphenyl-3(or 4)-carboxamide and N-bensyl-5-phenyl-thiophene-2- carboxamide was designed and the compounds were synthesized in a two to three steps reaction.
Journal ArticleDOI
Synthesis and Biological Evaluation of Spiro-δ-lactones as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 2 (17β-HSD2)
Journal ArticleDOI
Triazole Ring‐Opening Leads to the Discovery of Potent Nonsteroidal 17β‐Hydroxysteroid Dehydrogenase Type 2 Inhibitors.
TL;DR: A small library of novel non-steroidal and non-chiral 17β-HSD2 inhibitors is designed, synthesized and evaluated in a cell-free assay using human placental microsomal enzyme.